Better Context → Better Decisions
Context counts in life sciences. The Celltelligence analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers with corporate access can use our library to search all of the content already delivered to their inbox. If you think a colleague would enjoy receiving our content, reach out to the Celltelligence team to make it happen.
Free
Posted in: Allogeneic, CAR-T, CD19 Jun 06 | 2021Precision Improves Response Rates With an Enhanced LD; Is ALLO-501A’s Efficacy Good Enough? How Will CRISPR Tx Compare to Precision and Allogene in the CD19 CAR-T Space? ASCO 2021 Day 2Access Free Blast
Free
Posted in: Allogeneic, CAR-T, CD19 Jun 06 | 2021Updated Interim Results from PBCAR0191’s Ph1/2a Trial; New Details Provided for PBCAR19B Stealth CAR-T Program; Precision’s Pre-ASCO CD19 EventAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 Jun 05 | 2021Comparison of Kymriah’s and Breyanzi’s Efficacy Profile; Gilead Presents Updated Results from Tecartus’s Ph1/2 ZUMA-3 (ALL) and Ph2 ZUMA-2 (MCL) Trials; ASCO 2021 Day 1Access Free Blast
Free
Posted in: Autologous, CAR-T, CD19 Jun 04 | 2021Taking BMS to Court: Will Ex-Celgene’s Shareholders Recover Anything From the Failed CVR?Access Free Blast
Free
Posted in: Autologous, CAR-T Jun 04 | 2021Thoughts on Tmunity’s Decision to Drop TmPSMA-01: Will Companies Opt for More CAR-T Engineering or Better Drugs to Manage MAS?Access Free Blast
Free
Posted in: Allogeneic, CAR-T Jun 02 | 2021Spotlight on Bayer’s and Takeda’s Cell Therapy Strategy Part 2Access Free BlastFree
Posted in: Autologous, BCMA, CAR-T Jun 01 | 2021Canada Approves BMS’s Abecma (BCMA CAR-T) in ≥4L R/R MM; Will the Earliest Reimbursement Occur in 2022?Access Free BlastFree
Posted in: Allogeneic, CAR-T Jun 01 | 2021Spotlight on Bayer’s and Takeda’s Cell Therapy Strategy Part IAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T May 27 | 2021JNJ / Legend Receive Priority Review for Cilta-cel in MM; Approval Before Thanksgiving?Access Free Blast
Free
Posted in: Allogeneic, CAR-T, CD22 May 26 | 2021Cellectis Adds 4 Novel Cell Therapy Assets to Their Pipeline; Could UCARTFAP Become a Standard Backbone Therapy in Solid Tumors? Cellectis’s Innovation Series Day 2 SummaryAccess Free Blast
Free
Posted in: Allogeneic, CAR-T, CD19 May 20 | 2021ALLO-501A Ph2 Trial Likely to Include a Consolidation Regimen and Outpatient Administration; CD52 LD Regimens May Require Educational Outreach to Increase ALLO-501A Adoption; Allogene’s CD19 Forum SummaryAccess Free BlastFree
Posted in: Autologous, CAR-T, CD19 May 19 | 2021Breyanzi’s Reimbursement in Japan Matched to Kymriah’s and Yescarta’sAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T May 19 | 2021Cilta-cel’s Submission on Track in the US, Europe, China, and Japan; Multiple Cilta-cel Clinical Updates Expected at ASCO and EHA 2021; Legend Q1 2021 Earnings SummaryAccess Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD19 May 17 | 2021No Mention of Abecma, Breyanzi, or Cilta-cel in May's CHMP AgendaAccess Free Blast
Free
Posted in: Allogeneic, BCMA, CAR-T, CD19 May 13 | 2021Precision BioSciences Provides No Major Clinical Updates; Q1 2021 Earnings Call SummaryAccess Free Blast
Free
Posted in: Allogeneic, CAR-T, CD123, CD19, CD22, CS1 May 12 | 2021Cellectis Partners with Sanofi for Anti-CD52 Antibody Alemtuzumab Over ALLO-647; Could Sanofi Apply Alemtuzumab Learnings to Kiadis’s Pipeline?Access Free Blast
Free
Posted in: CAR-T, CD19 May 10 | 2021New Gilead-Sponsored Post-Marketing Trial for Tecartus (ZUMA-2 Cohort 3) in R/R MCLAccess Free Blast
Free
Posted in: Allogeneic, Autologous, BCMA, CAR-T, CD123, CD19, CD22, CS1, TCR May 07 | 2021Will Next-Generation Modules be Enough to Differentiate Autolus’s Products? Ziopharm Deprioritizes Several Programs; What Targets and Indications Could Cellectis Pursue Next? Autolus, Ziopharm, and Cellectis Q1 2021 Earnings Call SummariesAccess Free Blast
Free
Posted in: Autologous, BCMA, CAR-T, CD19 May 06 | 2021Allogene Doses First Patients With ALLO-316 (CD70 CAR-T) and Presents Novel TurboCARs for Solid Tumors; bluebird’s Oncology Newco Renamed as 2seventy bio; Allogene and bluebird bio Q1 2021 Earnings Call SummariesAccess Free Blast
Free
Posted in: Allogeneic, Autologous, CAR-T, Dual/triple agonist, TCR May 05 | 2021ACGT Summit Round-Up: Strategies to Overcome the Challenges of Solid Tumor TargetingAccess Free BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact us.